Blog
Latest articles, insights, and updates from the blog.
Beyond 'Less Bad': Rethinking Treatment-Resistant Depression
New clinical thinking on treatment-resistant depression urges aggressive care aimed at full remission — not just symptom reduction. Here's what it means for patients.
Faster TRD Remission: What Better Protocols Mean for You
New guidance on TRD treatment highlights faster dose adjustment and symptom tracking. Here's what it means for patients considering ketamine.
Getting TRD Patients to Remission Faster in 2026
New analysis in Psychiatric Times shows measurement-based care and rapid dose adjustment get TRD patients to remission faster — here's what that means for ketamine.
How Active Clinical Management Speeds Up TRD Recovery
New analysis shows faster symptom tracking and dose adjustments lead to quicker TRD remission—here's what that means for ketamine therapy.
BPL-003 Shows Lasting Relief for Treatment-Resistant Depression
New phase 2a results for BPL-003 show sustained symptom reduction in treatment-resistant depression. What this means for ketamine patients.
A Chicago Fund Is Bridging Ketamine's Coverage Gap
A Chicago nonprofit is stepping in where insurers won't, covering ketamine treatment costs for patients with depression who can't afford to wait.
A Chicago Fund Is Closing Ketamine's Access Gap
A Chicago nonprofit is stepping in where insurers won't, funding ketamine treatment for depression patients who can't afford out-of-pocket costs.
Esketamine's Role in Treatment-Resistant Depression
Clinicians are turning to esketamine for TRD and suicidal depression. Here's what patients need to know about access, cost, and how it compares to IV ketamine.
Why Settling for 'Less Bad' Depression Isn't Enough
Clinicians are pushing for aggressive TRD care aimed at full remission. Here's what that means for patients exploring ketamine treatment options.
BXCL501 Enters Phase 2a Trial for Acute Stress & PTSD
A new DoD-backed Phase 2a trial is testing BXCL501 for acute stress reactions. Here's what it means for the evolving PTSD treatment landscape.
BPL-003 Shows Lasting TRD Relief in Phase 2a Results
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. Here's what it means for ketamine patients.
New Ketamine Nasal Spray Shows Lasting Depression Relief
BPL-003, a novel ketamine nasal spray for treatment-resistant depression, shows sustained symptom reduction in Phase 2a trials. What patients should know.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.